Corebridge Financial Inc. Reduces Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Corebridge Financial Inc. lowered its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 7.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 51,761 shares of the biopharmaceutical company’s stock after selling 3,907 shares during the period. Corebridge Financial Inc.’s holdings in Revance Therapeutics were worth $157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in RVNC. Oddo BHF Asset Management Sas acquired a new stake in Revance Therapeutics during the third quarter worth $3,763,000. FNY Investment Advisers LLC grew its holdings in shares of Revance Therapeutics by 160.4% during the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock worth $1,452,000 after purchasing an additional 294,323 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Revance Therapeutics during the 3rd quarter worth about $2,315,000. State Street Corp raised its holdings in Revance Therapeutics by 6.6% in the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after buying an additional 150,323 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Revance Therapeutics by 11.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 265,210 shares of the biopharmaceutical company’s stock valued at $1,376,000 after buying an additional 27,420 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on RVNC. Barclays dropped their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, StockNews.com assumed coverage on Revance Therapeutics in a research report on Friday. They issued a “hold” rating on the stock. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Price Performance

Revance Therapeutics stock opened at $3.65 on Tuesday. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $6.65. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The company’s 50 day moving average is $3.65 and its two-hundred day moving average is $3.94.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.